{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:02:37Z","timestamp":1761894157145},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.beha.2005.01.030","type":"journal-article","created":{"date-parts":[[2005,7,17]],"date-time":"2005-07-17T12:33:11Z","timestamp":1121603591000},"page":"709-727","source":"Crossref","is-referenced-by-count":65,"title":["Amyloidosis"],"prefix":"10.1016","volume":"18","author":[{"given":"Morie A.","family":"Gertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2005.01.030_bib1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/path.1553","article-title":"Cleavage of AL amyloid proteins and AL amyloid deposits by cathepsins B, K, and L","volume":"203","author":"Bohne","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.beha.2005.01.030_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s004280050471","article-title":"Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence","volume":"436","author":"Linke","year":"2000","journal-title":"Virchows Arch"},{"key":"10.1016\/j.beha.2005.01.030_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/jsbi.2000.4221","article-title":"Review: history of the amyloid fibril","volume":"130","author":"Sipe","year":"2000","journal-title":"J Struct Biol"},{"key":"10.1016\/j.beha.2005.01.030_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002281-199401000-00010","article-title":"Proteins of the systemic amyloidoses","volume":"6","author":"Cohen","year":"1994","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.beha.2005.01.030_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1023\/B:JOCI.0000029113.68758.9f","article-title":"Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL)","volume":"24","author":"Abraham","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.beha.2005.01.030_bib6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0002-9343(89)90293-3","article-title":"Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome","volume":"86","author":"Kroenke","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.beha.2005.01.030_bib7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1309\/PFUGHBX0TY20E08U","article-title":"Bone marrow core biopsy specimens in AL (primary) amyloidosis: a morphologic and immunohistochemical study of 100 cases","volume":"120","author":"Swan","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2005.01.030_bib8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1053\/ajkd.2000.16205","article-title":"AL-amyloidosis of the kidney initially presenting as minimal change glomerulonephritis","volume":"36","author":"Hetzel","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.beha.2005.01.030_bib9","first-page":"129","article-title":"Paraproteinaemic neuropathy","volume":"3","author":"Thomas","year":"1994","journal-title":"Baillieres Clin Neurol"},{"key":"10.1016\/j.beha.2005.01.030_bib10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0002-9343(98)00037-0","article-title":"Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy","volume":"104","author":"Rajkumar","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.beha.2005.01.030_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000091183.93122.c7","article-title":"Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients","volume":"82","author":"Park","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.beha.2005.01.030_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0272-6386(97)90485-6","article-title":"Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976\u20131979 and 1995\u20131997","volume":"30","author":"Haas","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.beha.2005.01.030_bib13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.amjcard.2003.12.025","article-title":"Diagnosis of cardiac amyloidosis based on the myocardial velocity profile in the hypertrophied left ventricular wall","volume":"93","author":"Oki","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beha.2005.01.030_bib14","first-page":"201","article-title":"Cardiac amyloidosis","volume":"97","author":"Kingman","year":"2001","journal-title":"J S C Med Assoc"},{"key":"10.1016\/j.beha.2005.01.030_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0303-8467(94)90022-1","article-title":"Amyloid and peripheral nervous system disease","volume":"96","author":"Haan","year":"1994","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.beha.2005.01.030_bib16","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0025-6196(12)65706-1","article-title":"Primary systemic amyloidosis: a diagnostic primer","volume":"64","author":"Gertz","year":"1989","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.beha.2005.01.030_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.2830450214","article-title":"Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis)","volume":"45","author":"Solomon","year":"1994","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2005.01.030_bib18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1309\/LYWM47K2L8XYFFB3","article-title":"Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis","volume":"119","author":"Abraham","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2005.01.030_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00041552-200211000-00013","article-title":"Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis","volume":"11","author":"Hawkins","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.beha.2005.01.030_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1432-2277.2000.tb01047.x","article-title":"Liver transplantation as rescue treatment in a patient with primary AL kappa amyloidosis","volume":"13","author":"Nowak","year":"2000","journal-title":"Transpl Int"},{"key":"10.1016\/j.beha.2005.01.030_bib21","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.4065\/77.12.1287","article-title":"Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy","volume":"77","author":"Andrews","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.beha.2005.01.030_bib22","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1309\/Y6CYXF4ELL1GKQBU","article-title":"Biochemical subtyping of amyloid in formalin-fixed tissue samples confirms and supplements immunohistologic data","volume":"121","author":"Kaplan","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2005.01.030_bib23","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa013354","article-title":"Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis","volume":"346","author":"Lachmann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2005.01.030_bib24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00005792-199107000-00002","article-title":"Secondary systemic amyloidosis: response and survival in 64 patients","volume":"70","author":"Gertz","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"supplement 1","key":"10.1016\/j.beha.2005.01.030_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/13506129.2003.12088568","article-title":"Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations","volume":"10","author":"Westermark","year":"2003","journal-title":"Amyloid"},{"key":"10.1016\/j.beha.2005.01.030_bib26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1440-1827.1998.tb03919.x","article-title":"An immunohistochemical study of amyloid P component, apolipoprotein E and ubiquitin in human and murine amyloidoses","volume":"48","author":"Cui","year":"1998","journal-title":"Pathol Int"},{"key":"10.1016\/j.beha.2005.01.030_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/13506120009146836","article-title":"Histochemical and immunohistochemical differential diagnosis of amyloidosis: a brief illustrated essay and personal experience with Romhanyi's method","volume":"7","author":"Bely","year":"2000","journal-title":"Amyloid"},{"key":"10.1016\/j.beha.2005.01.030_bib28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2005.01.030_bib29","first-page":"443","article-title":"Hereditary systemic amyloidosis with renal involvement","volume":"16","author":"Hawkins","year":"2003","journal-title":"J Nephrol"},{"key":"10.1016\/j.beha.2005.01.030_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0268-960X(03)00027-4","article-title":"Therapy for immunoglobulin light chain amyloidosis: the new and the old","volume":"18","author":"Gertz","year":"2004","journal-title":"Blood Rev"},{"key":"10.1016\/j.beha.2005.01.030_bib31","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0735-1097(96)00202-1","article-title":"Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis","volume":"28","author":"Tei","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beha.2005.01.030_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11864-000-0018-9","article-title":"Primary systemic amyloidosis","volume":"1","author":"Comenzo","year":"2000","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.beha.2005.01.030_bib33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2002-06-1698","article-title":"Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.01.030_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/13506120209114100","article-title":"Beta-2 microglobulin serum levels and prediction of survival in AL amyloidosis","volume":"9","author":"Zerbini","year":"2002","journal-title":"Amyloid"},{"key":"10.1016\/j.beha.2005.01.030_bib35","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2005.01.030_bib36","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2005.01.030_bib37","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant. Blood 2004;104:1881\u20131887.","DOI":"10.1182\/blood-2004-01-0390"},{"key":"10.1016\/j.beha.2005.01.030_bib38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V77.2.257.257","article-title":"Response rates and survival in primary systemic amyloidosis","volume":"77","author":"Gertz","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.01.030_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2003.04433.x","article-title":"Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy","volume":"122","author":"Lachmann","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.01.030_bib40","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1046\/j.1365-2141.2001.02859.x","article-title":"A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis","volume":"113","author":"Palladini","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.01.030_bib41","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.4065\/75.12.1264","article-title":"Primary localized amyloidosis of the urinary bladder: a case series of 31 patients","volume":"75","author":"Tirzaman","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.beha.2005.01.030_bib42","first-page":"320","article-title":"Localized amyloidosis of the genito-urinary tract","volume":"88","author":"Mark","year":"1995","journal-title":"J R Soc Med"},{"key":"10.1016\/j.beha.2005.01.030_bib43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1365-2133.2001.04291.x","article-title":"Nodular localized primary cutaneous amyloidosis: a long-term follow-up study","volume":"145","author":"Woollons","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.beha.2005.01.030_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/0003-4819-124-4-199602150-00004","article-title":"Pulmonary amyloidosis: the Mayo Clinic experience from 1980 to 1993","volume":"124","author":"Utz","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2005.01.030_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1440-1843.2001.00298.x","article-title":"Pulmonary presentations of amyloidosis","volume":"6","author":"Howard","year":"2001","journal-title":"Respirology"},{"key":"10.1016\/j.beha.2005.01.030_bib46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/00313020212466","article-title":"Soft tissue amyloidoma (letter)","volume":"34","author":"Khoo","year":"2002","journal-title":"Pathology"},{"key":"10.1016\/j.beha.2005.01.030_bib47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.bmt.1702178","article-title":"Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report","volume":"25","author":"Gertz","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.01.030_bib48","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","article-title":"Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival","volume":"19","author":"Dispenzieri","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2005.01.030_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1703155","article-title":"High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis","volume":"28","author":"Kumar","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.01.030_bib50","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","article-title":"Autologous stem cell transplantation for primary systemic amyloidosis","volume":"99","author":"Comenzo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.01.030_bib51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1704346","article-title":"High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial","volume":"33","author":"Sanchorawala","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.01.030_bib52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2005.01.030_bib53","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1083-8791(03)00106-X","article-title":"Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study","volume":"9","author":"Blum","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2005.01.030_bib54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428199709059685","article-title":"Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation","volume":"27","author":"Desikan","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2005.01.030_bib55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1704344","article-title":"Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome","volume":"33","author":"Mollee","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.01.030_bib56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0002-9343(02)01208-1","article-title":"Stem cell transplantation for the management of primary systemic amyloidosis","volume":"113","author":"Gertz","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.beha.2005.01.030_bib57","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","article-title":"Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case\u2013control study","volume":"103","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.01.030_bib58","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-83-2-281","article-title":"Improvement in amyloidosis (letter)","volume":"83","author":"Horne","year":"1975","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2005.01.030_bib59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1445-5994.1978.tb04507.x","article-title":"The successful treatment of primary amyloidosis with intermittent chemotherapy","volume":"8","author":"Bradstock","year":"1978","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.beha.2005.01.030_bib60","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(78)91895-0","article-title":"Resolution of amyloidosis and plasma-cell dyscrasia with combination chemotherapy (letter)","volume":"2","author":"Corkery","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2005.01.030_bib61","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/10428190009065839","article-title":"FISH demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis","volume":"39","author":"Fonseca","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2005.01.030_bib62","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archinte.150.3.629","article-title":"Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis","volume":"150","author":"Gertz","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beha.2005.01.030_bib63","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood.V93.3.1062","article-title":"Long-term survival (10 years or more) in 30 patients with primary amyloidosis","volume":"93","author":"Kyle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.01.030_bib64","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2005.01.030_bib65","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.beha.2005.01.030_bib66","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1365-2141.2002.03541.x","article-title":"Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis","volume":"117","author":"Sanchorawala","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.01.030_bib67","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/bjc.1998.577","article-title":"The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone","volume":"78","author":"Wardley","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.beha.2005.01.030_bib68","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.bmt.1701765","article-title":"Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support","volume":"23","author":"Sezer","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.01.030_bib69","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/13506120209114818","article-title":"AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation","volume":"9","author":"van Gameren","year":"2002","journal-title":"Amyloid"},{"key":"10.1016\/j.beha.2005.01.030_bib70","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/10428199709059690","article-title":"Treatment of AL-amyloidosis with dexamethasone plus alpha interferon","volume":"27","author":"Dhodapkar","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2005.01.030_bib71","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF02785843","article-title":"Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis","volume":"16","author":"Gertz","year":"1999","journal-title":"Med Oncol"},{"key":"10.1016\/j.beha.2005.01.030_bib72","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/(SICI)1096-8652(199906)61:2<115::AID-AJH7>3.0.CO;2-I","article-title":"Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light chain amyloidosis","volume":"61","author":"Gertz","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2005.01.030_bib73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.beha.2005.01.030_bib74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/13506120309041743","article-title":"Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis","volume":"10","author":"Dispenzieri","year":"2003","journal-title":"Amyloid"},{"key":"10.1016\/j.beha.2005.01.030_bib75","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1385\/MO:20:3:283","article-title":"Etanercept therapy in patients with advanced primary amyloidosis","volume":"20","author":"Hussein","year":"2003","journal-title":"Med Oncol"},{"key":"10.1016\/j.beha.2005.01.030_bib76","first-page":"P132","article-title":"Dendritic cell-based idiotype vaccination for primary systemic amyloidosis and post transplant multiple myeloma (abstract)","author":"Lacy","year":"2001","journal-title":"Proc VIII Int Myeloma Workshop"},{"key":"10.1016\/j.beha.2005.01.030_bib77","first-page":"95","article-title":"Nc-531 (Neurochem)","volume":"5","author":"Geerts","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.beha.2005.01.030_bib78","first-page":"3831S","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2005.01.030_bib79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","article-title":"Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis","volume":"417","author":"Pepys","year":"2002","journal-title":"Nature"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T07:53:37Z","timestamp":1586332417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692605000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S1521692605000319"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2005.01.030","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}